Long-term follow-up of a trial comparing post-remission treatment with autologous or allogeneic bone marrow transplantation or intensive chemotherapy in younger acute myeloid leukemia patients

Even though the optimal post-remission therapy for younger acute myeloid leukemia (AML) patients has remained controversial[1][1] only a few prospective trials have been comparing intensive chemotherapy to autologous (auto-) or allogeneic (allo-) bone marrow transplantation (BMT). In addition, most